Diagnostic Value of Circulating PIGF in Combination with Flt-1 in Early Cervical Cancer

Abstract

The utility of placental growth factor (PlGF) and its receptor VEGFR-1 (Flt-1) as biomarkers for cervical cancer has not been clarified yet. To address this issue, we investigated the levels of soluble PlGF (sPlGF) and soluble Flt-1 (sFlt-1) in the serum from patients with early cervical cancer, cervical intraepithelial neoplasia (CIN) and controls in this study. sPlGF and sFlt-1 were detected in 44 preoperative patients with cervical cancer, 18 cases with CIN, and 20 controls by ELISA. It was found that both sPlGF and sFlt-1 were significantly increased in the cervical cancer group as compared with those in CIN and control groups. sPlGF presented a high diagnostic ability of cervical cancer, with a sensitivity of 61.36% and a specificity of 89.47%; and sFlt-1 with a sensitivity of 50.00% and a specificity of 92.11%. Importantly, the combined use of sPlGF and sFlt-1 could increase the diagnostic rate of cervical cancer, with a sensitivity of 70.45% and a specificity of 92.11%. These results indicated that both sPlGF and sFlt-1 in circulation can serve as possible valuable diagnostic biomarkers for cervical cancer, and the combined use of them can be more valuable to diagnose the patients with early cervical cancer.

Keywords

cervical cancer / placental growth factor / sFlt-1 / biomarker

References

[1] FerlayJ, SoerjomataramI, DikshitR, et al.. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5): E359-386

[2] StaflA, MattinglyRF. Angiogenesis of cervical neopl asia. Am J Obstet Gynecol, 1975, 121(6): 845-852

[3] BremerGL, TieboschAT, van der PuttenHW, et al.. Tumor angiogenesis: an independent prognostic parameter in cervical cancer. Am J Obstet Gynecol, 1996, 174(1Pt1): 126-131

[4] CaoY, ChenH, ZhouL, et al.. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem, 1996, 271(6): 3154-3162

[5] MaglioneD, GuerrieroV, VigliettoG, et al.. Isolation of a human placenta cDNA coding for a protein relation to the vascular permeability factor. Proc Natl Aacd Sci USA, 1991, 88(20): 9267-9271

[6] MigdalM, HuppertzB, TesslerS, et al.. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem, 1998, 273(35): 22 272-22 278

[7] ParkJE, ChenHH, WinerJ, et al.. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem, 1994, 269(41): 25 646-25 654

[8] OdorisioT, SchietromaC, ZaccariaML, et al.. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci, 2002, 115: 2559-2567Pt 12

[9] BagleyRG, RenY, WeberW, et al.. Placental growth factor upregulation is a host response to antiangiogenic therapy. Clin Cancer Res, 2011, 17(5): 976-988

[10] OwenLA, UeharaH, CahoonJ, et al.. Morpholinomediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PLoS One, 2012, 7(3): e33576

[11] ZhuH, LiZ, MaoS, et al.. Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice. Cancer Gene Ther, 2011, 18(12): 884-896

[12] YangS, ChengH, CaiJ, et al.. PlGF expression in pre-invasive and invasive lesions of uterine cervix is associated with angiogenesis and lymphangiogenesis. APMIS, 2009, 117(11): 831-838

[13] YangS, ChengH, HuangZ, et al.. Circulating Soluble Neuropilin-1 in Patients with Early Cervical Cancer and Cervical Intraepithelial Neoplasia Can Be Used as a Valuable Diagnostic Biomarker. Dis Markers, 2015, 2015: 506428

[14] KimKJ, ChoCS, KimWU. Role of placenta growth factor in cancer and inflammation. Exp Mol Med, 2012, 44(1): 10-19

[15] GadducciA, TanaR, CosioS, et al.. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol, 2008, 66(1): 10-20

[16] GuY, WanC, QiuJ, et al.. Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis. PLoS One, 2020, 15(2): e0224001

[17] MaG, SongG, ZouX, et al.. Circulating plasma microRNA signature for the diagnosis of cervical cancer. Cancer Biomark, 2019, 26(4): 491-500

[18] ZhengM, HouL, MaY, et al.. Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors. Mol Cancer, 2019, 18(1): 76

[19] YinS, YangM, LiX, et al.. Peripheral blood circulating microRNA-4636/-143 for the prognosis of cervical cancer. J Cell Biochem, 2020, 121(1): 596-608

[20] ShanthaK H, CabotJC, YanX, et al.. Minimally invasive colon resection is associated with a persistent increase in plasma PlGF levels following cancer resection. Surg Endosc, 2011, 25(7): 2153-2158

[21] ChengSJ, LeeJJ, ChengSL, et al.. Increased serum placenta growth factor level is significantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma. Oral Oncol, 2012, 48(5): 424-428

[22] HuangW, ZhuS, LiuQ, et al.. Placenta growth factor promotes migration through regulating epithelial-mesenchymal transition-related protein expression in cervical cancer. Int J Clin Exp Pathol, 2014, 7(12): 8506-8519

[23] RuffiniF, FaillaCM, OrecchiaA, et al.. Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: Role in tumour progression. Br J Dermatol, 2011, 164(5): 1061-1670

[24] NagaokaS, YoshidaT, AkiyoshiJ, et al.. The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol Rep, 2010, 23(6): 1647-1654

[25] DudaDG, WillettCG, AncukiewiczM, et al.. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist, 2010, 15(6): 577-583

[26] FanF, SamuelS, GaurP, et al.. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer, 2011, 104(8): 1270-1277

[27] KuemmelS, ThomasA, LandtS, et al.. Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer. Anticancer Res, 2009, 29(2): 641-645

[28] WuFT, StefaniniMO, Mac GabhannF, et al.. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med, 2010, 14(3): 528-552

[29] BertinS, Mohsen-KansonT, BaquéP, et al.. Tumor microenvironment modifications induced by soluble VEGF receptor expression in a rat liver metastasis model. Cancer Lett, 2010, 298(2): 264-272

[30] TakeiY, MizukamiH, SagaY, et al.. Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. Int J Cancer, 2007, 120(2): 278-284